Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma

NCT01265901 is registered in ClinicalTrials.gov with Immatics Biotechnologies GmbH as lead sponsor.

NCT NCT01265901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01265901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Lead sponsor
Immatics Biotechnologies GmbH
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
July 31, 2015
Enrollment
339 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma